Sign Out
Hypersensitivity to idarubicin or any other component of the product, other anthracyclines or anthracenediones.
Severe hepatic impairment.
Severe renal impairment.
Severe myocardial insufficiency.
Recent myocardial infarction.
Severe arrhythmias.
Persistent myelosuppression.
Previous treatment with maximum cumulative doses of idarubicin hydrochloride and/or other anthracyclines and anthracenediones (see Precautions).
